- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00807131
Effectiveness of Pharmaceutical Care on Primary Care Patients With Uncontrolled Hypertension (EPHACA)
Effectiveness of a Pharmaceutical Care Program on Primary Care Patients With Uncontrolled Hypertension- A Brazilian Multicenter RCT
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Inclusion and exclusion criteria: Potential hypertensive subjects aged above 18 years and and continuously receiving their medicines from the pharmacy are going to be identified through administrative data sources. They must take at least hydrochlorothiazide, and have no modifications on their hypertensive drug prescription on the last 2 months. Patients who have a serious psychiatric disorder or a severe cognitive impairment, blindness, pregnancy or secondary hypertension will be excluded. To be considered eligible, the patients should have a mean systolic and diastolic blood pressure above 140 mmHg and 90 mmHg at the screening visit if there were no COM morbidities associated, and above 130 mmHg and 80 mmHg for high-risk patients, using the validated Omron Hern-705-CP upper arm automated monitor.
Strategy/process by which participants/centres will be selected and recruited to the trial: Research assistants will invite the potential subjects when they attend the pharmacy to take their medicines or via telephone calls. By this moment, they will confirm eligibility and proceed the BP measures. If eligible for the study, the participant will receive all the trial explanations and the written informed consent will be obtained.
Randomization: The random allocation will be stratified by gender through a computer-generated sequence, individually for each centre. To maintain cancel allocation status, opaque, numbered and sealed envelopes will be adopted.
Interventions: Three different kinds of pharmacist services will be adopted, with growing complexity levels: drug dispensing, counseling and patient follow-up for 8 months. These methods are part of the Brazilian pharmaceutical care agreement, developed on the year of 2002, and will be compared with the pharmacy usual care. Seven pharmacists and 12 students were in charge of the pharmaceutical care program. All of them were trained in a 20 hour-course. Procedures details are written in a manual of operations, willing to standardize the interventions.
Outcomes: The primary outcomes are the BP differences between the one measured at 8-month follow-up and the baseline BP and the adherence, determined by 2 ways: a) measurement of plasma levels of hydrochlorothiazide, measured at the beginning and at the end of the study; b) drugs refill along the 8-months prior the randomization and during the 8-months of the trial. The occurrence of drug-related problems will be evaluated as a secondary outcome.
Blindness: Open-label study. Sample size: The study was design to enroll 304 patients equally distributed within the 4 centers, to provide 80% of statistical power to reject the null hypothesis and an error of 5% (two-tailed). Sampling size was calculated on the basis of a standard deviation of 10 mmHg, powered to detect clinically meaningful differences in mean changes of 5 mmHg between usual care and the intervention arms at 8-months follow-up, considering a 20% of drop-outs. Analyses will be conducted on intention-to-treat basis.
• Statistics: To assess for any differences among the intervention groups, the baseline characteristics will be compared performing Pearson χ2 test for categorical variables and F tests for continuous variables, and Fisher Exact test or Kruskal-Wallis if necessary. For the primary outcomes, the same tests will be applied. Analysis of covariance will be used when necessary.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasilien
- Mauro Silveira de Castro
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Potential hypertensive subjects aged above 18 years and and continuously receiving their medicines from the pharmacy are going to be identified through administrative data sources.
- They must take at least hydrochlorothiazide, and have no modifications on their hypertensive drug prescription on the last 2 months.
- To be considered eligible, the patients should have a mean systolic and diastolic blood pressure above 140 mmHg and 90 mmHg at the screening visit if there were no COM morbidities associated, and above 130 mmHg and 80 mmHg for high-risk patients.
Exclusion Criteria:
- Patients who have a serious psychiatric disorder or a severe cognitive impairment, blindness, pregnancy or secondary hypertension will be excluded.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Versorgungsforschung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: 1
Patient follow-up
|
Dader method, which was developed to provide pharmaceutical care, which consists of seven steps covering the evaluation of services, benefits of interventions, and identification of unexpected occurrences.
Its objectives are to improve the patient quality of life.
Andere Namen:
|
Experimental: 2
Counseling
|
The pharmacist proceeds the counseling when the patient comes to the pharmacy to take their medicines.
Andere Namen:
|
Experimental: 3
Drug dispensing
|
The pharmacist gives the drugs to the patient with the minimum of information necessary to guarantee a safe and effective drug intake.
Andere Namen:
|
Aktiver Komparator: 4
pharmacy usual care
|
The patient receives no information about their medicines in the pharmacy, unless he asks for it.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Blood pressure
Zeitfenster: 8 months
|
8 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
adherence
Zeitfenster: 8 months
|
8 months
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Mauro Castro, PhD, Federal University of Health Science of Porto Alegre
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 402736/2005-2
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Hypertonie
-
Nantes University HospitalBeendetZirrhotischer Patient mit Verdacht auf portale Hypertension und im Rahmen eines OV-ScreeningsFrankreich
Klinische Studien zur Patient follow-up
-
Vestre Viken Hospital TrustUniversity of Oslo; Oslo University Hospital; University of Bergen; Haukeland University...Rekrutierung
-
Istanbul University - Cerrahpasa (IUC)AbgeschlossenUnfruchtbarkeit | Psychische Belastung | Unfruchtbarkeit, weiblich | Depressionen, Angst | Die Rolle der KrankenschwesterTruthahn
-
University of CalgaryUniversity of British ColumbiaAbgeschlossenKnie Arthrose | Totale KnieendoprothetikKanada
-
H. Lee Moffitt Cancer Center and Research InstituteAbgeschlossenKrebsVereinigte Staaten
-
University of UtahStanford UniversityAbgeschlossen
-
Assistance Publique - Hôpitaux de ParisAbgeschlossen
-
University College of AntwerpKU Leuven; University Hospital, Antwerp; Universiteit AntwerpenUnbekannt
-
Dana-Farber Cancer InstituteAbgeschlossenBrustkrebs | Prostatakrebs | Patientenbindung | Patientenzufriedenheit | PatientenpräferenzVereinigte Staaten
-
VA Eastern Colorado Health Care SystemNoch keine Rekrutierung
-
Assiut UniversityRekrutierungAnomalien des Müller-GangsÄgypten